Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年4月25日
	新闻
	Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC ... PR Newswire It has already shown significant positive results in three Phase III trials for lung cancer, including 1) treatment for EGFR-TKI-resistant NSCLC, 2) ... 标记为不相关
	Rare lung cell found to protect against COVID-19 death News-Medical.Net ... Lung Cancer Cells. Ha-Rim Kim, Chinese Journal of Integrative Medicine. Gastric Metastases from Breast Cancer: A Case Report. YANG Lin, Medical ... 标记为不相关
	Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval Endpoints News Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes will top Merck's ... 标记为不相关
	AI in Cancer Care, Targeted Therapies Among Cancer Conference Talks - OncLive OncLive While progress has been made with new medicines, such as sotorasib and adagrasib, being approved for patients with K-Ras (G12C) lung cancer, drug ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈